Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?

Author(s):
Tielen, R.; Verhoef, C.; Coevorden, F. van; Gelderblom, H.; Sleijfer, S.; Hartgrink, H.H.; Bonenkamp, J.J.; Graaf, W.T. van der; Wilt, J.H.W. de
Published
2012
Publication type
Article / Letter to editor
Gastrointestinal stromal tumorsimatiniboverall survivalprogression-free survivalsurgerysunitinib
Date issued
2012-06-15
Language
English
Is part of
World Journal of Surgical Oncology (2012), Vol. 10, p. -
hdl
1887/99037
doi
10.1186/1477-7819-10-111